ALAmy T. Larkin

Amy T. Larkin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amy T. Larkin has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Adrienne Stevens

    Teachers College, Columbia University, WebMD, Mount Sinai School of Medicine, New York, New York, USA

    1 shared publication
  • Andrew Douglas

    Teachers College, Columbia University, WebMD, Mount Sinai School of Medicine, New York, New York, USA

    1 shared publication
  • Christina Hoffman

    MS. Group Vice President. Quality and Strategy, Medscape Education. New York, NY (United States).

    1 shared publication
  • Christopher P. Cannon

    Brigham and Women’s Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA

    1 shared publication
  • Colleen S. Ma Healy

    From *Medscape Education, New York, NY; †CGH Medical Center, Sterling, IL; and ‡Johns Hopkins University School of Medicine, Baltimore, MD

    1 shared publication
  • Deepak L. Bhatt

    Brigham and Women’s Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA

    1 shared publication

Latest Publications

  • Quality Improvement in Management of Acute Coronary Syndrome: Continuing Medical Education and Peer Coaching Improve Antiplatelet Medication Adherence and Reduce Hospital Readmissions

    by Amy Larkin, Michael MA LaCouture, Kathleen PharmD Geissel, Peri Barr, Eric R. Bates, Christopher P. Cannon, Deepak L. Bhatt

    Background: Reducing hospital readmissions and improving patient adherence to antiplatelet medications after an acute coronary syndrome (ACS) event are important goals for improving patient health and decreasing healthcare costs. Nearly half of patients will have a secondary event within 1 year of the initial ACS event. Quality improvement (QI) initiatives that include continuing medical education and peer coaching may improve physician practice patterns and, therefore, patient outcomes. Methods: This study evaluated the impact of a QI initiative on antiplatelet (P2Y12 inhibitor) medication adherence (measured via pharmacy fill rates postdischarge) and hospital readmissions. Results: Notable physician performance and patient-level changes included significant increases in antiplatelet medication counseling at hospital discharge (30%–57%; P < 0.0001), in P2Y12 inhibitor prescribing at hospital discharge (76%–84%; P = 0.02), and in patient fill rates for branded P2Y12 inhibitors (72%–100%; P = 0.0001). There were numerical trends toward lower rates of ACS-related rehospitalizations at 60 days postdischarge (from 11% to 7%; P = 0.15) and of all-cause rehospitalizations at 60 days (from 20% to 14%; P = 0.10). Conclusion: Important in the rapidly evolving landscape of quality healthcare, QI involving continuing medical education and peer coaching demonstrably impacted physician performance and patient outcomes after an ACS event.


  • Determinants of adherence to diabetes treatment

    by Amy T. Larkin, Christina Hoffman, Adrienne Stevens, Andrew Douglas, Zachary Bloomgarden

    Background: Understanding and improving medication adherence is crucial in diabetes management. Adherence to a diabetes regimen can improve glucose control and limit the development of complications. The aim of the present study was to evaluate the extent to which a variety of factors influence diabetes medication adherence.Methods: A medication adherence survey was made available on WebMD, a medical information website for patients and/or consumers. Respondents were residents of the US, ≥18 years old, and diagnosed with either type 1 or type 2 diabetes mellitus (self‐reported).Results: Behavioral adherence (self‐reported doses missed per week) correlated with perceived adherence (patients' self‐report of their overall impression of medication adherence, ranked 0–5; P < 0.001). Adherent patients (very few [0%–10%] issues with adherence) were more likely to report having received information from their physician. Mostly adherent patients (few [11%–26%] issues with adherence) were less likely to obtain information from their physician, but reported more medication self‐titration. Somewhat non‐adherent patients (some [27%–46%] adherence issues) reported more “self‐consciousness factors” and hypoglycemia. Non‐adherent patients (many [47%–88%] adherence issues) were more likely to report worries about medication side effects.Conclusions: Receiving information from a healthcare provider is associated with greater diabetes medication adherence, suggesting the importance of clinicians making time to provide patient education.


  • Knowledge of PCSK9 and Continued Educational Gaps

    by Amy T. Larkin, Colleen S. Ma Healy, Peter P. Toth

    Reducing serum levels of low-density lipoprotein–cholesterol (LDL-C) is an important treatment objective in both the primary and secondary prevention settings. Although statin therapy remains the gold standard for reducing LDL-C, for a variety of reasons, many patients taking statins do not achieve adequate cholesterol lowering. This has created a need for new treatment approaches to manage dyslipidemia. One potential emerging treatment option to promote greater LDL-C reduction is the class of proprotein convertase subtilisin/kexin 9 (PCSK9) monoclonal antibodies, currently in phase 3 development. This study evaluated the impact of continuing medical education (CME) on increasing knowledge and awareness of the role of PCSK9 in lipid metabolism and analyzed persistent educational gaps to determine needs for future education. For cardiologists who participated in the CME activity, comparison of individually linked preassessment question responses to their respective postassessment question responses demonstrated improvement (n = 83; P < 0.05). Correct responses on postassessment questions ranged between 63% and 253% higher after CME, with an overall effect size of 0.72. Between 24% and 47% of learners showed improvement in understanding individual learning concepts. In the ever-evolving landscape of dyslipidemia management, CME demonstrably impacted knowledge of the PCSK9 monoclonal antibodies.